By Myles Starr
Increasing the indications for the use of glucagon-like peptide-1 (GLP-1) agonist drugs, such as semaglutide (marketed as Ozempic and Wegovy by Novo Nordisk, with wholesale acquisition costs of, respectively, $968.52 and $1,349.02), beyond glucose control has increased their use. In the year between February 2022 and February 2023, prescribing of GLP-1 agonists for diabetes and obesity was up 128% and 352%, respectively.
The International Foundation of Employee Benefit Plans